XML 55 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Summary of Total Stock-Based Compensation Expense
The following table presents total stock-based compensation expense recorded in the consolidated statements of operations and comprehensive income (loss) for all awards granted under the Company’s 2013 Plan and 2011 Plan:
 
Three Months Ended
March 31,
 
2019
 
2020
 
(unaudited, in thousands)
Cost of revenue
$
915

 
$
739

Sales and marketing
1,754

 
1,938

Engineering and development
1,333

 
1,092

General and administrative
5,014

 
6,067

Total stock-based compensation expense
$
9,016

 
$
9,836
Summary of Stock Options
The following table provides a summary of the Company’s stock options as of March 31, 2020 and the stock option activity for all stock options granted under the 2013 Plan during the three months ended March 31, 2020:
 
Stock
Options
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual
Term
(in years)
 
Aggregate
Intrinsic
Value(3)
(in thousands)
 
(unaudited)
Outstanding at December 31, 2019
5,276,679

 
$
10.57

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
—

 
$
—

 
 
 
 
Forfeited
(674
)
 
$
11.10

 
 
 
 
Expired
(119,716
)
 
$
10.16

 
 
 
 
Outstanding at March 31, 2020
5,156,289

 
$
10.58

 
6.5
 
$
—

Exercisable at March 31, 2020
4,141,636

 
$
11.22

 
6.1
 
$
—

Expected to vest after March 31, 2020(1)
1,014,653

 
$
7.97

 
8.4
 
$
—

Exercisable as of March 31, 2020 and expected to vest (2)
5,156,289

 
$
10.58

 
6.5
 
$
—

(1) 
This represents the number of unvested options outstanding as of March 31, 2020 that are expected to vest in the future.
(2) 
This represents the number of vested options as of March 31, 2020 plus the number of unvested options outstanding as of March 31, 2020 that are expected to vest in the future.
(3) 
The aggregate intrinsic value was calculated based on the positive difference, if any, between the estimated fair value of the Company’s common stock on March 31, 2020 of $1.93 per share, or the date of exercise, as appropriate, and the exercise price of the underlying options.
The following table provides a summary of the Company’s stock options as of March 31, 2020 and the stock option activity for all stock options granted under the 2011 Plan during the three months ended March 31, 2020:
 
Stock
Options
 
Weighted-
Average
Exercise
Price
 
Weighted-
Average
Remaining
Contractual Term
(In Years)
 
Aggregate
Intrinsic
Value(3)
(in thousands)
 
(unaudited)
Outstanding at December 31, 2019
533,547

 
$
8.83

 
 
 
 
Granted
—

 
$
—

 
 
 
 
Exercised
(3,597
)
 
$
3.68

 
 
 
 
Forfeited
(1,277
)
 
$
9.43

 
 
 
 
Expired
(26,694
)
 
$
7.74

 
 
 
 
Outstanding at March 31, 2020
501,979

 
$
8.92

 
1.7
 
$
—

Exercisable at March 31, 2020
492,688

 
$
8.92

 
1.7
 
$
—

Expected to vest after March 31, 2020(1)
9,291

 
$
9.09

 
3.5
 
$
—

Exercisable as of March 31, 2020 and expected to vest (2)
501,979

 
$
8.92

 
1.7
 
$
—

(1) 
This represents the number of unvested options outstanding as of March 31, 2020 that are expected to vest in the future.
(2) 
This represents the number of vested options as of March 31, 2020 plus the number of unvested options outstanding as of March 31, 2020 that are expected to vest in the future.
(3) 
The aggregate intrinsic value was calculated based on the positive difference, if any, between the estimated fair value of the Company’s common stock on March 31, 2020 of $1.93 per share, or the date of exercise, as appropriate, and the exercise price of the underlying options.
Summary of Restricted Stock Awards and Restricted Stock Units The following table provides a summary of the Company’s restricted stock unit activity for the 2013 Plan during the three months ended March 31, 2020:
 
Restricted Stock
Units
 
Weighted-
Average
Grant Date
Fair Value
 
(unaudited)
Non-vested at December 31, 2019
9,005,109

 
$
6.90

Granted
8,548,413

 
$
3.90

Vested
(1,295,109
)
 
$
7.92

Canceled
(337,795
)
 
$
6.55

Non-vested at March 31, 2020
15,920,618

 
$
5.22


The following table provides a summary of the Company’s restricted stock award activity for the 2013 Plan during the three months ended March 31, 2020:
 
Restricted Stock
Awards
 
Weighted-
Average
Grant Date
Fair Value
 
(unaudited)
Non-vested at December 31, 2019
159,517

 
$
10.68

Granted
—

 
$
—

Vested
(5,675
)
 
$
8.15

Canceled
(1,466
)
 
$
11.10

Non-vested at March 31, 2020
152,376

 
$
10.77


The following table provides a summary of the Company’s restricted stock unit activity for the 2011 Plan during the three months ended March 31, 2020:
 
Restricted Stock
Units
 
Weighted-
Average
Grant Date
Fair Value
 
(unaudited)
Non-vested at December 31, 2019
320,142

 
$
8.35

Granted
—

 
$
—

Vested
(5,823
)
 
$
7.44

Canceled
(27,855
)
 
$
8.66

Non-vested at March 31, 2020
286,464

 
$
8.34